ICM
CVS icon

Invenomic Capital Management’s CVS Health CVS Stock Holding History

Invenomic Capital Management’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-56,578
Closed -$2.54M – 177
2024
Q4 		$2.54M Buy
+56,578
New +$3.17M 0.12% 140
2024
Q2 		– Sell
-189,996
Closed -$15.2M – 170
2024
Q1 		$15.2M Buy
189,996
+35,949
+23% +$2.75M 0.81% 48
2023
Q4 		$12.2M Sell
154,047
-111,529
-42% -$7.94M 0.55% 62
2023
Q3 		$18.5M Buy
265,576
+52,356
+25% +$3.71M 0.78% 41
2023
Q2 		$14.7M Buy
213,220
+106,577
+100% +$7.58M 0.75% 43
2023
Q1 		$7.92M Buy
+106,643
New +$8.94M 0.45% 66
2020
Q4 		– Sell
-6,188
Closed -$361K – 149
2020
Q3 		$361K Sell
6,188
-660
-10% -$41.1K 0.2% 108
2020
Q2 		$445K Sell
6,848
-15,870
-70% -$999K 0.33% 90
2020
Q1 		$1.35M Sell
22,718
-38,000
-63% -$2.54M 1.1% 30
2019
Q4 		$4.51M Buy
+60,718
New +$4.26M 1.81% 14

Other funds holding CVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Invenomic Capital Management's CVS Position: Q1 2025 in Review

Invenomic Capital Management sold out of CVS Health (CVS) in Q1 2025, closing a stake of 56,578 shares — an estimated $2.54M sold.

Invenomic Capital Management first reported a position in CVS in Q4 2019 and held it in 10 quarters. The position peaked at $18.5M in Q3 2023. 1,756 funds tracked by Wall St. Rank hold CVS as of Q1 2025.

  • Invenomic Capital Management reported no remaining CVS Health position as of Q1 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 56,578 CVS Health shares in Q1 2025, an estimated $2.54M.
  • Invenomic Capital Management first reported a position in CVS Health in Q4 2019 and held it in 10 quarters.
  • Invenomic Capital Management's CVS Health position peaked at $18.5M in Q3 2023.
  • 1,756 funds tracked by Wall St. Rank held CVS Health as of Q1 2025.

Based on Invenomic Capital Management's 13F filing for Q1 2025, filed 15 May 2025.